140 related articles for article (PubMed ID: 35818933)
1. A novel methylated cell-free DNA marker panel to monitor treatment response in metastatic prostate cancer.
Peter MR; Bilenky M; Shi Y; Pu J; Kamdar S; Hansen AR; Fleshner NE; Sridhar SS; Joshua AM; Hirst M; Xu W; Bapat B
Epigenomics; 2022 Jul; 14(13):811-822. PubMed ID: 35818933
[No Abstract] [Full Text] [Related]
2. Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform.
Lin E; Hahn AW; Nussenzveig RH; Wesolowski S; Sayegh N; Maughan BL; McFarland T; Rathi N; Sirohi D; Sonpavde G; Swami U; Kohli M; Rich T; Sartor O; Yandell M; Agarwal N
Oncologist; 2021 Sep; 26(9):751-760. PubMed ID: 34157173
[TBL] [Abstract][Full Text] [Related]
3. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
[TBL] [Abstract][Full Text] [Related]
4. Cell-free DNA concentration and fragment size as a biomarker for prostate cancer.
Chen E; Cario CL; Leong L; Lopez K; Márquez CP; Chu C; Li PS; Oropeza E; Tenggara I; Cowan J; Simko JP; Chan JM; Friedlander T; Wyatt AW; Aggarwal R; Paris PL; Carroll PR; Feng F; Witte JS
Sci Rep; 2021 Mar; 11(1):5040. PubMed ID: 33658587
[TBL] [Abstract][Full Text] [Related]
5. Chromosomal Instability in Cell-free DNA as a Prognostic Biomarker of Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy.
Lee CU; Cho E; Lee J; Lim JE; Chung JH; Song W; Kang M; Sung HH; Jeong BC; Seo SI; Jeon SS; Lee HM; Jeon HG
Eur Urol Focus; 2023 Jan; 9(1):89-95. PubMed ID: 36167777
[TBL] [Abstract][Full Text] [Related]
6. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
Wyatt AW; Azad AA; Volik SV; Annala M; Beja K; McConeghy B; Haegert A; Warner EW; Mo F; Brahmbhatt S; Shukin R; Le Bihan S; Gleave ME; Nykter M; Collins CC; Chi KN
JAMA Oncol; 2016 Dec; 2(12):1598-1606. PubMed ID: 27148695
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate Cancer.
Fettke H; Kwan EM; Bukczynska P; Ng N; Nguyen-Dumont T; Southey MC; Davis ID; Mant A; Parente P; Pezaro C; Hauser C; Azad AA
Eur Urol Focus; 2021 Nov; 7(6):1287-1291. PubMed ID: 32739405
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients.
Hendriks RJ; Dijkstra S; Smit FP; Vandersmissen J; Van de Voorde H; Mulders PFA; van Oort IM; Van Criekinge W; Schalken JA
Prostate; 2018 Apr; 78(5):336-342. PubMed ID: 29330943
[TBL] [Abstract][Full Text] [Related]
9. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
[TBL] [Abstract][Full Text] [Related]
10. Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer.
Tulpule V; Morrison GJ; Falcone M; Quinn DI; Goldkorn A
Curr Oncol Rep; 2022 Oct; 24(10):1287-1298. PubMed ID: 35575959
[TBL] [Abstract][Full Text] [Related]
11. Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer.
Peter MR; Bilenky M; Davies A; Isserlin R; Bader GD; Fleshner NE; Hirst M; Zoubeidi A; Bapat B
Sci Rep; 2021 Mar; 11(1):6630. PubMed ID: 33758253
[TBL] [Abstract][Full Text] [Related]
12. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer.
Barault L; Amatu A; Siravegna G; Ponzetti A; Moran S; Cassingena A; Mussolin B; Falcomatà C; Binder AM; Cristiano C; Oddo D; Guarrera S; Cancelliere C; Bustreo S; Bencardino K; Maden S; Vanzati A; Zavattari P; Matullo G; Truini M; Grady WM; Racca P; Michels KB; Siena S; Esteller M; Bardelli A; Sartore-Bianchi A; Di Nicolantonio F
Gut; 2018 Nov; 67(11):1995-2005. PubMed ID: 28982739
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment.
Peter MR; Bilenky M; Isserlin R; Bader GD; Shen SY; De Carvalho DD; Hansen AR; Hu P; Fleshner NE; Joshua AM; Hirst M; Bapat B
Epigenomics; 2020 Aug; 12(15):1317-1332. PubMed ID: 32867540
[No Abstract] [Full Text] [Related]
14. BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.
Fettke H; Dai C; Kwan EM; Zheng T; Du P; Ng N; Bukczynska P; Docanto M; Kostos L; Foroughi S; Brown S; Graham LK; Mahon K; Horvath LG; Jia S; Kohli M; Azad AA
EBioMedicine; 2023 Sep; 95():104738. PubMed ID: 37549632
[TBL] [Abstract][Full Text] [Related]
15. Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
Mahon KL; Qu W; Lin HM; Spielman C; Cain D; Jacobs C; Stockler MR; Higano CS; de Bono JS; Chi KN; Clark SJ; Horvath LG
Eur Urol; 2019 Sep; 76(3):306-312. PubMed ID: 30466891
[TBL] [Abstract][Full Text] [Related]
16. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
Annala M; Struss WJ; Warner EW; Beja K; Vandekerkhove G; Wong A; Khalaf D; Seppälä IL; So A; Lo G; Aggarwal R; Small EJ; Nykter M; Gleave ME; Chi KN; Wyatt AW
Eur Urol; 2017 Jul; 72(1):34-42. PubMed ID: 28259476
[TBL] [Abstract][Full Text] [Related]
17. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
[TBL] [Abstract][Full Text] [Related]
18. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
[TBL] [Abstract][Full Text] [Related]
19. Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer.
García-Ortiz MV; Cano-Ramírez P; Toledano-Fonseca M; Cano MT; Inga-Saavedra E; Rodríguez-Alonso RM; Guil-Luna S; Gómez-España MA; Rodríguez-Ariza A; Aranda E
Clin Epigenetics; 2023 Jul; 15(1):118. PubMed ID: 37481552
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
Sonpavde G; Agarwal N; Pond GR; Nagy RJ; Nussenzveig RH; Hahn AW; Sartor O; Gourdin TS; Nandagopal L; Ledet EM; Naik G; Armstrong AJ; Wang J; Bilen MA; Gupta S; Grivas P; Pal SK; Lanman RB; Talasaz A; Lilly MB
Cancer; 2019 May; 125(9):1459-1469. PubMed ID: 30620391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
